FDA approves Susvimo for diabetic macular edema
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
Feb 6, 2025
0
18
MeSH tree: D12.776.124.486.485.114.224.060.868
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
Feb 6, 2025
0
18
Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Dec 30, 2024
0
20
A University at Buffalo researcher who is a leading expert on retinopathy of prematurity (ROP) has published a study that could change the standard of care for the condition. ROP occurs in low birthweight premature babies; ...
May 13, 2024
0
47
For patients with minimally active or inactive uveitis and persistent or recurrent uveitic macular edema (ME), dexamethasone is significantly better for treatment than methotrexate or ranibizumab, according to a study published ...
Jun 22, 2023
0
30
Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a clinical trial. Compared with ...
Jun 13, 2023
0
40